SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 8-A/A
AMENDMENT NO. 1
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(B) OR 12(G) OF THE
SECURITIES EXCHANGE ACT OF 1934
ADVANCED TISSUE SCIENCES, INC.
(Exact name of registrant as specified in charter)
DELAWARE 0-016607 14-1701513
(State of incorporation (Commission (IRS Employer
or organization) File Number) Identification No.)
10933 North Torrey Pines Road, La Jolla, California, 92037
(Address of principal executive offices)
Registrant's telephone number, including area code: (858) 713-7300
Securities to be registered pursuant to Section 12(b) of the Act:
NONE
(TITLE OF CLASS)
Securities to be registered pursuant to Section 12(g) of the Act:
PREFERRED SHARE PURCHASE RIGHTS
(Title of Class)
NASDAQ NATIONAL MARKET SYSTEM
(Name of Exchange)
<PAGE>
Item 1. Description of Registrant's Securities to be Registered.
-------------------------------------------------------
On November 10, 1999, Advanced Tissue Sciences, Inc. (the "Company"),
completed a public offering of units (the "Offering") sold by the Company to
the State of Wisconsin Investment Board ("SWIB"). The units were sold
directly by the Company under Registration Statement No. 333-82683 on Form S-3.
In connection with the Company's sale of units, on November 5, 1999, the
Company entered into a Securities Purchase Agreement with SWIB (the "SWIB
Purchase Agreement"). Under the SWIB Purchase Agreement, the Company agreed,
among other things, to, prior to the completion of the Offering, amend the
Rights Agreement dated as of January 6, 1995, (the "Rights Agreement") by and
between the Company and ChaseMellon Shareholder Services, L.L.C., a New Jersey
Limited Liability Company (formerly Chemical Trust Company of California), as
Rights Agent (the "Rights Agent"). The Company's Board of Directors approved
an amendment (the "Amendment") to the Rights Agreement as set forth on attached
Exhibit 1. All capitalized terms used below and not defined herein have the
- ---------
meanings given them in the Rights Agreement, as amended.
The Amendment essentially provides that:
1. the definition of "Acquiring Person" shall not include SWIB, but
only to the extent that (1) SWIB first becomes the Beneficial Owner of in
excess of 15% of the Company's Common Shares solely as a result of SWIB
entering into the SWIB Purchase Agreement, in the ordinary course of its
business and not with the purpose or effect of influencing the control of the
Company (or in connection with or as a participant in any transaction having
such purpose or effect) and (2) at any time subsequent thereto, SWIB does not
beneficially own any more than 19.99% of the Company's Common Shares (the
"Beneficial Ownership Limitation"); and
2. in the case of SWIB, the Distribution Date shall not be deemed to
occur and the Rights will not separate from the Company's Common Shares until
a tender or exchange offer is commenced the consummation of which would cause
SWIB to beneficially own Common Shares of the Company in excess of the
Beneficial Ownership Limitation.
The foregoing description of the Amendment does not purport to be
complete and is qualified in its entirety by reference to the full text of the
Amendment and the SWIB Purchase Agreement filed herewith.
<PAGE>
Item 2. Exhibits.
--------
1. First Amendment to Rights Agreement entered into as of November 8, 1999,
between ChaseMellon Shareholders Services, L.L.C., as Rights Agent and
Advanced Tissue Sciences, Inc.
2. Securities Purchase Agreement dated as of November 5, 1999, between the
State of Wisconsin Investment Board and Advanced Tissue Sciences, Inc.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act
of 1934, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereto duly authorized.
ADVANCED TISSUE SCIENCES, INC.
DATE: November 10, 1999 By: /s/ Arthur J. Benvenuto
---------------------------------
Name: Arthur J. Benvenuto
-------------------------------
Title: Chairman of the Board and
Chief Executive Officer
------------------------------
<PAGE>
EXHIBIT INDEX
Exhibit
Number Document Description
------- --------------------
1 First Amendment to Rights Agreement entered into as of
November 8, 1999, between ChaseMellon Shareholders Services,
L.L.C. and Advanced Tissue Sciences, Inc.
2 Securities Purchase Agreement dated as of November 5, 1999,
between the State of Wisconsin Investment Board and Advanced
Tissue Sciences, Inc.
Exhibit 1
FIRST AMENDMENT TO RIGHTS AGREEMENT
THIS AMENDMENT (the "Amendment") is entered into as of November 8, 1999, by
and between ADVANCED TISSUE SCIENCES, INC., a Delaware corporation (the
"Company"), and CHASEMELLON SHAREHOLDERS SERVICES, L.L.C., a New Jersey Limited
Liability Company (formerly CHEMICAL TRUST COMPANY OF CALIFORNIA, as Rights
Agent (the "Rights Agent").
Recitals
--------
A. The Company and the Rights Agent are parties to a Rights Agreement dated
as of January 6, 1995 (the "Rights Agreement").
B. The State of Wisconsin Investment Board ("SWIB"), and the Company have
entered into, among other agreements, a Securities Purchase Agreement dated as
of November 5, 1999 (the "SWIB Purchase Agreement"), pursuant to which SWIB is
to purchase 3,750,000 Units (as defined in the SWIB Purchase Agreement). Each
Unit will separate on issuance into one share of common stock of the Company,
par value $.01 per share, and a warrant to purchase 0.46666666 of a share of
common stock.
C. Pursuant to Section 5.2 of the SWIB Purchase Agreement, the Company's
Board of Directors has determined that an amendment to the Rights Agreement as
set forth herein is necessary and desirable to reflect the foregoing and certain
other matters, and the Company and the Rights Agent desire to evidence such
amendment in writing.
Accordingly, the parties agree that:
1. Certain Definitions. Section 1 of the Rights Agreement shall be
----------------------------------------------------------------
amended as follows:
- ------------------
(a) The definition of "Acquiring Person" in subsection (a) shall be
deleted and replaced as follows:
"Acquiring Person" shall mean any Person (as defined below) who
or which,together with all Affiliates and Associates (as such terms are
defined below) of such Person, shall be the Beneficial Owner (as defined
below) of 15% or more of the Company's Common Shares (as defined below)
then outstanding, but shall not include (1) the Company, any Subsidiary
(as defined below) of the Company, any employee benefit plan of the
Company or of a Subsidiary of the Company, or any entity holding the
Company's Common Shares for or pursuant to the terms of any such plan or
(2) the State of Wisconsin Investment Board (the "Permitted Investor" or
"SWIB"), but only to the extent that (1) the Permitted Investor first
becomes the Beneficial Owner of in excess of 15% of the Company's Common
Shares solely as a result of the Permitted Investor entering into the SWIB
Purchase Agreement (as defined below) in the ordinary course of
<PAGE>
its business and not with the purpose or effect of changing or influencing
the control of the Company (or in connection with or as a participant in
any transaction having such purpose or effect) and (2) at any time
subsequent thereto the Permitted Investor does not "beneficially own" (as
defined below) any more than 19.99% of the Company's Common Shares (the
"Beneficial Ownership Limitation").
In addition, no current holder of the Company's Common Shares
shall be deemed an "Acquiring Person" by reason of such holder's holdings
at the date of the Rights Agreement, prior to any amendments thereto,
unless such holder (other than the Permitted Investor) shall increase its
holdings by more than 2% of the Company's outstanding Common Shares, or,
in the case of the Permitted Investor, unless the Permitted Investor
shall increase its holdings above the Beneficial Ownership Limitation,
but any new Person that becomes the Beneficial Owner of the holdings of
such current holder shall be deemed an Acquiring Person.
Notwithstanding the foregoing, no Person shall become an Acquiring
Person as the result of an acquisition of Common Shares by the Company
which, by reducing the number of shares outstanding, (a) increases the
proportionate number of shares beneficially owned by such Person to 15%
or more of the Company's Common Shares then outstanding or, (b) in the
case of the Permitted Investor, increases the proportionate number of the
Company's Common Shares owned by the Permitted Investor to more than the
Beneficial Ownership Limitation; provided, however, that if, by reason
-------- -------
of share purchases by the Company, (1) a Person (other than the Permitted
Investor) shall become the Beneficial Owner of 15% or more of the Company's
Common Shares then outstanding or, (2) in the case of the Permitted
Investor, the amount of the Company's Common Shares the Permitted Investor
beneficially owns increases to exceed the Beneficial Ownership Limitation,
and, in the case of (1) or (2) shall, after such share purchases by the
Company, become the Beneficial Owner of any additional Common Shares of
the Company, then such Person, including without limitation the Permitted
Investor, shall be deemed to be an Acquiring Person.
Notwithstanding the foregoing, if the Company's Board of Directors
determines in good faith that a Person who would otherwise be an Acquiring
Person, as defined pursuant to the foregoing provisions of this paragraph
(a), is eligible to file and did file a Schedule 13G and such Person
divests as promptly as practicable a sufficient number of the Company's
Common Shares so that such Person would no longer be an Acquiring Person,
as defined pursuant to the foregoing provisions of this paragraph (a),
then such Person shall not be deemed to be an Acquiring Person for any
purpose of this Agreement.
(b) The definition of "Trading Day" shall be moved to subsection (ii)
and the following definition shall replace such definition as subsection
(hh): "SWIB Purchase Agreement" shall mean that certain Securities
Purchase Agreement dated as of November 5, 1999, by and between the
Company and SWIB.
<PAGE>
2. Amendment of Section 3(a).
-------------------------
The first sentence of Section 3(a) of the Rights Agreement is amended to
read in its entirety as follows:
(a) Until the earlier of (i) the tenth Business Day after the Shares
Acquisition Date or (ii) the tenth Business Day (or such later, date as
may be determined by action of the Board of Directors prior to such time
as any Person becomes an Acquiring Person) after the date of the
commencement by any Person (other than the Company, any Subsidiary of
the Company, any employee benefit plan of the Company or of any Subsidiary
of the Company, or any entity holding the Company's Common Shares for or
pursuant to the terms of any such plan) of, or of the first public
announcement of the intention of any Person (other than the Company, any
Subsidiary of the Company, any employee benefit plan of the Company or
of any Subsidiary of the Company, or any entity holding the Company's
Common Shares for or pursuant to the terms of any such plan) to commence,
a tender or exchange offer the consummation of which would result in any
Person becoming the Beneficial Owner of the Company's Common Shares
aggregating 15% or more of the Company's then outstanding Common Shares
or, in the case of the Permitted Investor, which would cause the Permitted
Investor to beneficially own Company Common Shares in excess of the
Beneficial Ownership Limitation (including any such date which is after
the date of this Agreement and prior to the issuance of the Rights; the
earlier of such dates being herein referred to as the "Distribution
Date"), (x) the Rights will be evidenced (subject to the provisions of
Section 3(b) hereof) by the certificates for the Company's Common
Shares registered in the names of the holders thereof (which certificates
shall also be deemed to be Right Certificates) and not by separate Right
Certificates, and (y) the right to receive Right Certificates will be
transferable only in connection with the transfer of the Company's Common
Shares. As soon as practicable after the Distribution Date, the Company
will notify the Rights Agent thereof and the Company will prepare and
execute, the Rights Agent will countersign, and the Company will send or
cause to be sent (and the Rights Agent will, if requested and provided
with or given access to the necessary information, send) by first-class,
insured, postage-prepaid mail, to each record holder of the Company's
Common Shares as of the Close of Business on the Distribution Date, at
the address of such holder shown on the records of the Company, a Right
Certificate, in substantially the form of Exhibit B hereto (a "Right
Certificate"), evidencing one Right for each Common Share so held. As
of the Distribution Date, the Rights will be evidenced solely by such
Right Certificates.
3. Miscellaneous.
-------------
This Amendment shall be deemed to be a contract made under the laws of
the State of Delaware and for all purposes shall be governed by and construed
in accordance with the laws of such State applicable to contracts to be made
and performed entirely within such State. This Amendment may be executed in
any number of counterparts, each of such counterparts
<PAGE>
shall for all purposes be deemed to be an original, and all such counterparts
shall together constitute but one and the same instrument. If any term,
provision, covenant or restriction of this Amendment is held by a court of
competent jurisdiction or other authority to be invalid, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions of this
Amendment shall remain in full force and effect and shall in no way be affected,
impaired or invalidated.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed and attested, all as of the day and year first above written.
ATTEST: ADVANCED TISSUE SCIENCES, INC.,
a Delaware corporation
/s/ Arthur J. Benvenuto
------------------------------------
Name: /s/ Michael V. Swanson Name: Arthur J. Benvenuto
----------------------------- -------------------------------
Title: Senior Vice President Title: Chairman of the Board and
---------------------------- ------------------------------
and Chief Financial Officer Chief Executive Officer
---------------------------- ------------------------------
ATTEST: CHASEMELLON SHAREHOLDER SERVICES, L.L.C.
/s/ Martha Mijango
------------------------------------
Name: /s/ Sharon Knepper Name: Martha Mijango
---------------------------- -------------------------------
Title: Vice President Title: Assistant Vice President
--------------------------- -------------------------------
Exhibit 2
SECURITIES PURCHASE AGREEMENT
This Securities Purchase Agreement (this "Agreement"), dated as of November
5, 1999, is entered into by and between each of the parties who are designated
as Purchasers on the signature page to this Agreement (each, a "Purchaser" and
collectively, the "Purchasers") and Advanced Tissue Sciences, Inc., a Delaware
corporation (the "Company").
The Company has offered to sell, and each of the Purchasers has agreed to
purchase, the number of Units (as defined below) of the Company set forth
opposite their names on Schedule I attached hereto. This sale and purchase is
being made pursuant to a Prospectus (as defined below) dated November 5, 1999
filed in connection with a Registration Statement (as defined below) on Form
S-3, originally filed with the Securities and Exchange Commission on July 12,
1999, and subsequently amended. Such Registration Statement, as amended, when
it became effective (including (A) the information deemed to be part of the
Registration Statement at the time it became effective pursuant to Rule 430A of
the Rules and Regulations under the Securities Act of 1933, as amended, and (B)
the related registration statement filed pursuant to Rule 462(b) under the
Securities Act of 1933, as amended), is referred to herein as the "Registration
Statement" and such Prospectus in the form delivered for filing with the
Securities and Exchange Commission pursuant to Rule 424(b) is referred to herein
as the "Prospectus." Each "Unit" consists of one share of common stock of the
Company, $.01 par value per share (the "Common Stock"), and one Warrant (as
defined below), both of which will separate immediately upon issuance. Each
"Warrant" comprising a Unit entitles the holder to purchase up to 0.46666666 of
a share of Common Stock at an exercise price of $4.00 per share, subject to
adjustment pursuant to the terms of the Warrant, and is exercisable immediately
commencing on the date of the Warrant and ending three years from such date.
In connection therewith, the Company and each of the Purchasers, severally and
not jointly, hereby agree as follows:
1. Purchase and Sale of Shares. Subject to the terms set forth herein,
---------------------------
the Company agrees to sell to each of the Purchasers at a purchase price of
$4.00 per Unit (the "Per Unit Purchase Price") and to deliver pursuant to
Section 2 hereof the shares of Common Stock and Warrants purchased under the
Units, and upon the basis of the representations and warranties, and subject
to the terms set forth herein, each of the Purchasers agrees, severally and
not jointly, to purchase the number of Units set forth opposite its name on
Schedule I attached hereto from the Company for an amount equal to the Per
Unit Purchase Price multiplied by such number of Units set forth in Schedule
I (the "Purchase Price").
Notwithstanding the foregoing, in the event that the Company sells any
shares (or securities that may be converted into or exchanged for shares) of
Common Stock of the Company in an original issuance (not shares traded on the
Nasdaq National Market in the aftermarket) for less per share than the Per Unit
Purchase Price at any time during the sixty (60) day period commencing on the
Closing Date (except for shares issued pursuant to (a) stock options, (b)
purchases by the Company of outstanding existing stock options, and (c)
warrants, preferred stock and any other convertible securities, including
without limitation, the Units, outstanding as of the date hereof) the Company
shall have the obligation to promptly notify and pay each of the Purchasers (x)
the aggregate difference between (i) the Per Unit Purchase Price and (ii) the
per share price of such additional shares of the Company's Common Stock (or
securities that may be converted into or exchanged for shares of Common Stock)
so sold, (y) multiplied by the number of Units purchased
<PAGE>
hereunder, at the Company's option, in either cash or additional shares of the
Company's Common Stock. If the Company elects to pay in Common Stock, the
Common Stock shall be valued at the price at which the Company sold any such
shares (or securities that may be converted into or exchanged for shares) of
Common Stock in the specific transaction that triggered this paragraph of
Section 1 hereof and will be payable within five (5) days of the closing of
such other transaction.
If within sixty (60) days of the Closing Date hereof the Company enters
into or is a party to any agreement to issue additional shares of Common Stock
of the Company (or securities convertible or exchangeable therefor), the
Company shall provide notice of such issuance to the Purchaser as soon as
reasonably practicable.
2. Closing. The closing of the purchase and sale of the Units to all
-------
of the Purchasers shall take place at the same time, on the first business day
following the satisfaction of the conditions set forth in Paragraph 5 below, as
coordinated by the parties, or on such other date or at such other time and
place as the Company and the Purchasers may agree upon (such time and date of
the closing being referred to herein as the "Closing Date"). Upon payment of
the Purchase Price in full in immediately available funds by or on behalf of the
Purchasers to the Company by wire transfer to an account specified by the
Company to the Purchasers prior to the Closing Date, the Company will promptly
cause its transfer agent to deliver to the Purchasers certificates representing
the shares of Common Stock and the Company will deliver the Purchasers the
Warrants purchased under the Units in such denominations and registered in such
names as the Purchasers shall have requested not less than two business days
prior to the Closing Date.
3. Representations and Warranties of the Company.
---------------------------------------------
3.1 Organization; Good Standing; Qualification. The Company is a
------------------------------------------
corporation duly organized, validly existing, and in good standing under the
laws of the State of Delaware, has all requisite corporate power and authority
to own and operate its properties and assets and to carry on its business as now
conducted and as proposed to be conducted, to execute and deliver this
Agreement, to issue and sell the Units, and to carry out the provisions of this
Agreement.
3.2 Authorization. All corporate action on the part of the
-------------
Company, its officers, directors, and stockholders necessary for the
authorization, execution and delivery of this Agreement, the performance of all
obligations of the Company hereunder and the authorization, issuance (or
reservation for issuance), sale, and delivery of the Units has been taken or
will be taken prior to the Closing, and this Agreement constitutes the valid and
legally binding obligation of the Company, enforceable in accordance with its
terms, (i) except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors' and
contracting parties' rights generally, (ii) except as enforceability may be
subject to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law), and (iii)
except as the indemnification agreements in Section 6 hereof may be legally
unenforceable.
3.3 Valid Issuance of Units. The Units that are being purchased
------------------------
by the Purchaser hereunder, when issued, sold, paid for, and delivered in
accordance with the terms of this Agreement for the consideration expressed
herein, will be duly and validly issued, fully paid, and nonassessable. The
Units, including the underlying Common Stock, Warrants and the Common Stock
issuable upon the exercise of the Warrants, will be registered and qualified for
sale
2
<PAGE>
in compliance with all applicable federal and state securities laws and
will be free of restrictions on transfer other than restrictions under
applicable state and federal securities laws, including without limitation Rule
144 under the Securities Act of 1933. Notwithstanding the foregoing, although
the Common Stock is currently traded on the Nasdaq National Market, the Warrants
will not be traded on the Nasdaq National Market. Should Purchaser at any time
request in writing that the Warrants be traded on the Nasdaq National Market,
the Company will make commercially reasonable efforts to have the Warrants
listed on the Nasdaq National Market within a reasonably practicable time period
following such request by Purchaser provided that the Warrants meet the Nasdaq
National Market listing requirements in effect at the time of such request.
3.4 Performance of the Agreement. The making and performance of
----------------------------
the Agreement by the Company and the consummation of the transactions herein
contemplated will not violate any provision of the organizational documents of
the Company. The making and performance of the Agreement by the Company and the
consummation of the transactions herein contemplated will not (i) result in the
creation of any lien, charge, security interest or encumbrance upon any assets
of the Company pursuant to the terms or provisions of, or (ii) conflict with,
result in the breach or violation of, or constitute, either by itself or upon
notice or the passage of time or both, a default under, any material agreement,
mortgage, deed of trust, lease, franchise, license, indenture, permit or other
instrument to which the Company is a party or by which the Company or any of its
respective properties may be bound or affected, or, to the Company's knowledge,
any statute or any authorization, judgment, decree, order, rule or regulation of
any court or any regulatory body, administrative agency or other governmental
body applicable to the Company or any of its respective properties and, in each
case (i) or (ii), which individually or in the aggregate would have a material
adverse effect on the condition (financial or otherwise), properties, business,
prospects as of the date hereof or results of operations of the Company, taken
as a whole.
3.5 Additional Information. The Company represents and warrants
----------------------
that the information contained in the Registration Statement and Prospectus, as
amended in their final forms, will comply in all material respects with the
Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder and will be, true and complete in all material respects as of the
date of filing and as of the Closing Date.
3.6 Use of Proceeds. The Company agrees that the proceeds to the
---------------
Company from the sale of the Units may be used to fund existing operations,
provided that a portion of such proceeds equal to 105% of the liquidation value
of the Company's currently outstanding Series B Convertible Preferred Stock, par
value $.01 per share (the "Series B Preferred Stock"), but not to exceed
$5,000,000, shall be reserved to the extent necessary to redeem the Company's
Series B Preferred Stock in lieu of conversion as provided in Section 3.7 below.
3.7 Redemption in Lieu of Conversion. In respect to its
--------------------------------
outstanding Series B Preferred Stock, the Company agrees to deliver to the
holders of its Series B Preferred Stock a "Notice of Company Redemption in Lieu
of Conversion" as provided and to the extent permitted in Section 6 of the
Company's Certificate of Designations, Preferences and Rights of Series B
Convertible Preferred Stock.
3.8 Intellectual Property. The Company has the patent and
---------------------
intellectual property rights necessary to conduct its business as it is now
being conducted. No claim has been made
3
<PAGE>
against the Company regarding its alleged infringement of the intellectual
property or patent rights of others that would be expected to have a materially
adverse effect against the Company.
4. Representations and Warranties of the Purchaser. The Purchaser
-----------------------------------------------
represents and warrants, as of the date hereof, as follows:
4.1 the Purchaser has full right, power, authority and capacity to
enter into this Agreement and to consummate the transactions contemplated hereby
and has taken all necessary action to authorize the execution, delivery and
performance of this Agreement;
4.2 if applicable, the Purchaser is duly organized, validly
existing and in good standing under the laws of its jurisdiction;
4.3 the making and performance of the Agreement by Purchaser and
the consummation of the transactions herein contemplated will not violate any
provision of the organizational documents of Purchaser or conflict with, result
in the breach or violation of, or constitute, either by itself or upon notice or
the passage of time or both, a default under any material agreement, mortgage,
deed of trust, lease, franchise, license, indenture, permit or other instrument
to which the Purchaser is a party or, any statute or any authorization,
judgment, decree, order, rule or regulation of any court or any regulatory body,
administrative agency or other governmental body applicable to Purchaser;
4.4 the Purchaser is an institutional investor or otherwise exempt
from the reporting requirements of the Hart-Scott Rodino Antitrust Improvements
Act of 1976, as amended (and the regulations thereunder) with respect to this
transaction;
4.5 no consent, approval, authorization or other order of any
court, regulatory body, administrative agency or other governmental body is
required on the part of the Purchaser for the execution and delivery of this
Agreement or the consummation of the transactions contemplated by this
Agreement;
4.6 upon the execution and delivery of this Agreement, this
Agreement shall constitute a valid and binding obligation of the Purchaser
enforceable in accordance with its terms, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors' and contracting parties' rights generally
and except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law), and except as the indemnification agreements in Section 6
hereof may be legally unenforceable; and
4.7 there is not in effect any order enjoining or restraining the
Purchaser from entering into or engaging in any of the transactions contemplated
by this Agreement.
5. Conditions of Closing. The obligations of each party hereunder
---------------------
shall be subject to:
5.1 The accuracy in all material respects of the representations
and warranties of the other party hereto as of the date hereof.
5.2 The Company shall have amended its Rights Agreement between
the Company and ChaseMellon Shareholder Services, L.L.C. to provide that as long
as the State of
4
<PAGE>
Wisconsin Investment Board is acquiring securities of the Company in the
ordinary course of its business and not with the purpose or effect of
changing or influencing the control of the Company (or in connection with or
as a participant in any transaction having such purpose or effect) the
Purchaser will not be deemed to be an Acquiring Person, as defined therein,
solely by reason of its acquiring or having obtained the right to acquire
beneficial ownership of shares of the Common Stock under this Agreement or as a
result of any such subsequent acquisitions which would result in the Purchaser
being the beneficial owner of 15% or more of the Common Stock of the Company but
less than 19.99% of the Common Stock of the Company;
5.3 the Registration Statement has been declared effective and no
stop order suspending the effectiveness of the Registration Statement shall have
been issued;
5.4 The Purchaser shall have received the legal opinion of counsel
to the Company, in substantially the form set forth in Exhibit A hereto, with
such changes thereto as may be agreed upon by the Purchaser and such counsel;
and
5.5 The Company shall have terminated its Investment Agreement
with Hatteras Partners, L.P. dated February 9, 1996, as amended January 26, 1998
and July 10, 1998.
6. Indemnification.
---------------
6.1 The Company agrees to indemnify and hold harmless the
Purchaser, each person, if any, who controls the Purchaser within the meaning of
Section 15 of the Act and each officer and director, employee and agent of the
Purchaser and of any such controlling person against any and all liabilities,
claims, damages or reasonable expenses whatsoever, as incurred, arising out of,
or resulting from, any breach or other violation of any representation,
warranty, covenant or undertaking by the Company contained in this Agreement,
and the Company will reimburse the Purchaser for its reasonable legal and other
expenses (including the reasonable cost of any investigation and preparation,
and including the reasonable fees and expenses of counsel) incurred in
connection therewith.
6.2 The Purchaser agrees to indemnify and hold harmless the
Company, each person, if any, who controls the Company within the meaning of
Section 15 of the Act and each officer, director, employee and agent of the
Company and of any such controlling person against any and all losses,
liabilities, claims, damages or reasonable expenses whatsoever, as incurred,
arising out of, or resulting from, any breach or other violation of any
representation, warranty, covenant or undertaking by the Purchaser contained in
this Agreement, and the Purchaser will reimburse the Company for its reasonable
legal and other expenses (including the reasonable cost of any investigation and
preparation, and including the reasonable fees and expenses of counsel) incurred
in connection therewith.
7. Survival of Representations and Warranties. The respective
------------------------------------------
agreements, representations, warranties, indemnities and other statements made
by or on behalf of each party hereto pursuant to this Agreement, as of the date
they were made, shall, unless otherwise specified, survive until the third
anniversary of the Closing Date and shall expire thereafter.
5
<PAGE>
8. Miscellaneous.
-------------
8.1 This Agreement may be executed in two or more counterparts,
and such counterparts shall constitute one and the same agreement. Authorized
signatures may be evidenced to the other party by facsimile copies thereof, with
the originally signed signature page of any party to be provided to the other
parties after the original execution.
8.2 This Agreement shall inure to the benefit of and be binding
upon the signatories hereto and no other person shall have any right or
obligation hereunder. This Agreement may not be assigned by any party hereto.
8.3 This Agreement, together with the schedule and exhibit hereto,
constitutes the complete and entire agreement between the parties hereto with
respect to the subject matter hereof and supersedes any prior agreements or
understanding, whether written or oral, between the parties respective to such
subject matter. This Agreement may be amended only in a writing which is
executed by the Company and the Purchasers.
8.4 The Company and the Purchasers agree to cooperate with each
other to deliver such additional documents and instruments and take such further
actions as shall be necessary or appropriate under the terms of this Agreement
to effectuate the transactions contemplated hereby.
8.5 This Agreement shall be governed by the internal laws of the
State of California, without giving effect to the conflict of laws principles
thereof.
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered
this Agreement as of the date and year first above written.
ADVANCED TISSUE SCIENCES, INC.
By: /s/ Arthur J. Benvenuto
-------------------------------------
Name: Arthur J. Benvenuto
-------------------------------------
Its: Chairman of the Board and Chief
--------------------------------------
Executive Officer
--------------------------------------
STATE OF WISCONSIN INVENTMENT BOARD:
By: /s/ John F. Nelson
----------------------------------
Name: John F. Nelson
--------------------------------
Its: Investment Director
---------------------------------
6
<PAGE>
SCHEDULE I
SCHEDULE OF PURCHASERS
Name and Address of Number of Units
Purchasers To be Purchased
- ----------------------------------- ---------------------
State of Wisconsin Investment Board 3,750,000
121 East Wilson St.
Madison, Wisconsin 53702
Mailing Address:
P.O. Box 7842
Madison Wisconsin 53707
7
<PAGE>
EXHIBIT A
NOVEMBER [__], 1999
State of Wisconsin Investment Board
121 East Wilson Street
Madison, Wisconsin 53702
Re: Advanced Tissue Sciences, Inc.'s Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as counsel to Advanced Tissue Sciences, Inc., a Delaware
corporation (the "Company"), in connection with the issuance and sale by the
Company of Units, in the aggregate consisting of up to 3,750,000 shares (the
"Shares") of the Company's Common Stock, par value $.01 per share ("Common
Stock"), and warrants to purchase up to 1,750,000 shares of Common Stock
("Warrants") (together with the Shares, the "Securities") pursuant to that
certain Securities Purchase Agreement, dated November 5, 1999 (the "Purchase
Agreement"), between the Company and the State of Wisconsin Investment Board
(the "Purchaser"). This opinion is being rendered to you pursuant to Section
5.4 of the Purchase Agreement. Capitalized terms used but not defined herein
shall have the meanings ascribed to such terms in the Purchase Agreement.
In our capacity as counsel to the Company, we have examined, among other
things, originals, or copies identified to our satisfaction as being true
copies, of the following:
(i) The Registration Statement on Form S-3 (File No. 333-82683)
initially filed by the Company with the Securities and Exchange Commission (the
"Commission") on July 12, 1999, for the purpose of registering the sale of the
Securities under the Securities Act of 1933, as amended (the "Securities Act");
Amendment No. 1 to such Registration Statement filed with the Commission on
August 20, 1999; Amendment No. 2 to such Registration Statement filed with the
Commission on September 15, 1999; Amendment No. 3 to such Registration Statement
filed with the Commission on October 18, 1999; oral advice on November 4,
1999, from a Commission staff examiner, that the Commission had declared such
Registration Statement, as so amended, effective as of 4:30 p.m., Washington,
D.C. time, on November 4, 1999; and the final Prospectus in the form filed with
the Commission on November [__], 1999, pursuant to Rule 424(b) under the
Securities Act. Such Registration Statement, as amended, when it became
effective (including (A) the information deemed to be part of the Registration
Statement at the time it became effective pursuant to Rule 430A of the Rules and
Regulations under the Securities Act and (B) the related registration statement
filed pursuant to Rule 462(b) under the Securities Act), is referred to herein
as the "Registration Statement," and such Prospectus in the form delivered for
filing with the Commission pursuant to Rule 424(b) is referred to herein as the
"Prospectus;"
(ii) The Restated Certificate of Incorporation of the Company,
including all amendments thereto, as in effect on the date hereof (the
"Restated Certificate");
<PAGE>
(iii) The Amended and Restated By-laws of the Company, including all
amendments thereto, as in effect on the date hereof (the "By-laws");
(iv) The Certificate of Good Standing of the Company certified by the
Secretary of State of the State of Delaware on November [__], 1999 (the
"Delaware Certificate");
(v) The Certificate of Status of the Company certified by the
Secretary of State of the State of California on November [__], 1999 (the
"California Certificate").
(vi) Evidence of applicable actions by the Board and Pricing Committee
authorizing the execution and delivery of the Purchase Agreement, the issuance
and sale of the Securities sold by the Company, the preparation and filing of
the Registration Statement, and other actions with regard thereto;
(vii) The resolutions of the Pricing Committee of the Board of Directors
adopted on November 5, 1999, authorizing the pricing of the Securities;
(viii) The Purchase Agreement;
(ix) A specimen certificate for the shares of Common Stock of the
Company;
(x) Such records, certificates, documents and instruments, certified
or otherwise identified to our satisfaction, as we have considered necessary or
appropriate for the purposes of this opinion.
In addition, we have obtained from public officials and from officers and
other representatives of the Company such other certificates and assurances as
we consider necessary for purposes of this opinion. We have assumed the
accuracy of all copies provided to us, the legal capacity of the individual
signatories to all documents and the due authorization, execution and delivery
of the Purchase Agreement by you. We have also assumed the genuineness of all
signatures.
As used in this opinion, the expressions "to our knowledge" and "known to
us" with reference to matters of fact means that, after considering the actual
knowledge of those attorneys in our firm who have been principally responsible
for giving substantive attention to the Company's affairs, but not including any
constructive or imputed notice of any other information, we find no reason to
believe that the opinions expressed herein are factually incorrect. Beyond that
we have made no independent factual investigation for the purpose of rendering
an opinion with respect to such matters except as otherwise specified in this
opinion.
We have assumed that the certificates representing the Shares purchased
by you from the Company have been executed for delivery by authorized officers
of the transfer agent and that the signatures on all documents examined by us
are genuine, which assumptions we have not independently verified.
This opinion relates solely to the laws of the State of California, the
General Corporation Law of the State of Delaware and the federal securities
laws of the United States, and we express no opinion with respect to the effect
or applicability of the laws in other areas or of other
2
<PAGE>
jurisdictions. Without limiting the generality of the foregoing, we are not
acting here as experts on, and we do not express any opinion on any applicable
laws, rules or regulations relating to (i) patents, copyrights, trademarks and
other proprietary rights and licenses or (ii) the United States Food and Drug
Administration or health care reimbursement.
For purposes of the matters addressed in paragraph (1) below relating to
the valid existence and good standing of the Company under the laws of
Delaware, we have relied solely upon the Delaware Certificate. For purposes
of the matters addressed in paragraph (1) below relating to the good standing,
due qualification or similar status of the Company in California, we have
relied solely upon our review of the California Certificate.
For purposes of our opinion in paragraph (2) below, we have assumed that
the certificates representing the Shares will be manually signed by one of the
authorized officers of the Transfer Agent and Registrar of the Common Stock and
registered by such Transfer Agent and Registrar and will conform to the specimen
thereof examined by us.
For purposes of our opinion in paragraph (3) below, relating to the
Registration Statement being effective and there being no stop order suspending
the effectiveness of the Registration Statement, we have relied solely upon
(a) oral advice received on November [__], 1999, from a Commission staff
examiner, that the Commission had declared such Registration Statement, as
amended, effective at ______ p.m. Washington, D.C. time, on November [__],
1999 and (b) oral advice received on November [__], 1999 from a Commission
staff examiner that there is no stop order suspending the effectiveness of the
Registration Statement.
For purposes of our opinion in paragraph (3) below, relating to the filing
of the Prospectus pursuant to Rule 424(b), we have relied solely upon a
confirmation of filing received from the Commission's EDGAR filing system dated
November [__], 1999.
We express no opinion as to the fair market value of the Securities, nor
with respect to the effect of, or compliance with, any state or federal
antitrust law, any local law, or compliance with the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended.
On the basis of our examination of the foregoing, and subject to the
qualifications and limitations set forth herein, we are of the opinion that:
1. The Company is duly incorporated and is validly existing and in
good standing under the laws of the State of Delaware; the Company has the
corporate power and authority to own, lease and operate its properties and to
conduct its business as described in the Registration Statement and the
Prospectus (and any amendment or supplement thereto); the Company has the
corporate status and authority to do business in California;
2. The Securities have been duly authorized and, when issued and
delivered to you against payment therefor in accordance with the terms of the
Purchase Agreement, will be validly issued, fully paid and nonassessable and
free of (A) any preemptive rights arising under the Restated Certificate or
the Delaware General Corporation Law or (B) to our knowledge, similar rights
that entitle or will entitle any person to acquire any shares of capital stock
of the Company upon the issuance and sale of the Securities by the Company;
3
<PAGE>
3. The Registration Statement has become effective under the
Securities Act and, to our knowledge, no stop order suspending the effectiveness
of the Registration Statement has been issued and no proceedings for that
purpose are pending before or contemplated by the Commission; and any required
filing of the Prospectus pursuant to Rule 424(b) has been made in accordance
with Rule 424(b);
4. The Company has the corporate power and authority to enter into
the Purchase Agreement and to issue, sell and deliver the Securities to you as
provided in the Purchase Agreement. All corporate action on the part of the
Company, its directors and stockholders necessary for (a) the authorization,
execution and delivery of the Purchase Agreement, (b) the authorization, sale,
issuance and delivery of the Securities, and (c) the performance of the
Company's obligations under the Purchase Agreement has been taken;
5. Neither the offer, sale or delivery of the Securities, the
execution, delivery or performance by the Company of the Purchase Agreement,
compliance by the Company with the provisions of the Purchase Agreement nor
consummation by the Company of the transactions contemplated by the Purchase
Agreement violates the Restated Certificate or the By-laws of the Company;
6. No consent, approval, authorization or other order of, or
registration or filing with, any court, regulatory body, administrative agency
or other governmental body, agency, or official is required on the part of the
Company (except (A) as have been obtained under the Securities Act and the
Exchange Act of 1934 or (B) such as may be required under state securities or
Blue Sky laws governing the purchase and distribution of the Securities, as to
which we express no opinion) for the valid issuance and sale of the Securities
to you as contemplated by the Purchase Agreement; and
7. The Securities when duly registered under the Registration
Statement pursuant to the Securities Act will not be deemed "restricted
securities" as defined pursuant to Rule 144(a)(3) under the Securities Act.
This opinion is furnished by us as counsel to the Company, to you, the
Purchaser, in connection with the transactions contemplated by the Purchase
Agreement, is solely for your benefit and may not be delivered to, quoted or
relied upon by any other party, or for any other purpose, without our express
written consent. Our opinion is expressly limited to the matters set forth
above and we render no opinion, whether by implication or otherwise, as to any
other matters relating to the Company. We assume no obligation to advise you of
facts, circumstances, events or developments which hereafter may be brought to
our attention and which may alter, affect or modify the opinions expressed
herein.
Very truly yours,
4
